Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06273588 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 50 microgram PF-06273588 intravenous | EXPERIMENTAL | Subjects will receive a single intravenous microdose of PF-06273588 in period one |
| 50 microgram PF-06273588 oral | EXPERIMENTAL | Subjects will receive a single oral microdose of PF-06273588 in period two |
| Name | Type | Description |
|---|---|---|
| PF-06273588 | DRUG | Intravenous, 50 microgram, single dose |
Inclusion Criteria: * Healthy male subjects between the ages of 18 and 55 years (inclusive). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical...
PF-06273588 is an investigational small molecule developed by Pfizer, Inc. (ticker: PFE). It has been studied in a Phase 1 clinical trial in healthy male volunteers in the United Kingdom. The specific therapeutic indication for PF-06273588 has not been disclosed.
PF-06273588 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 clinical trial of PF-06273588 conducted in the United Kingdom.
PF-06273588 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA. The single Phase 1 trial of PF-06273588 has been completed.
PF-06273588 has been evaluated in one clinical trial: NCT01408355, titled "A Study To Investigate The Elimination Of PF-06273588 From The Body Following A Single Low Dose." This Phase 1 trial enrolled 5 healthy male volunteers in the United Kingdom and is completed.
The Phase 1 trial NCT01408355 investigated the elimination of PF-06273588 from the body following a single low dose. The study was controlled, enrolled 5 healthy male volunteers aged 18 years and older, and was conducted in the United Kingdom. The trial is completed.